Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 9020 results

  1. Percutaneous Laser Ablation (PLA) for benign thyroid nodules

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. Capsule endoscopy for oesophageal disease

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]

    In development Reference number: GID-TA11036 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]

    Awaiting development Reference number: GID-TA10717 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]

    Awaiting development Reference number: GID-TA11920 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Transoral Endoscopic Thyroid/Parathyroid Vestibular Approach

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  7. Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265]

    Awaiting development Reference number: GID-TA11307 Expected publication date:  06 January 2027

    Technology appraisal guidance
    Awaiting development

  8. Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]

    In development Reference number: GID-TA11154 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777]

    Awaiting development Reference number: GID-TA11292 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Epilepsies in children, young people and adults (extraordinary review)

    In development Reference number: GID-NG10378 Expected publication date: TBC

    NICE guideline
    In development

  11. Bipolar disorder: assessment and management (extraordinary review)

    In development Reference number: GID-NG10380 Expected publication date: TBC

    NICE guideline
    In development

  12. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with olaparib and chemoradiation for previously untreated limited-stage small-cell lung cancer [ID6412]

    Awaiting development Reference number: GID-TA11497 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 [TSID11839]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation